ProCE Banner Activity

Aperçu des nouvelles données sur les inhibiteurs BTK pour le traitement de la LLC et du LCM à l’occasion de la réunion annuelle de la SOHO 2022

Clinical Thought
LLC et LCM : réunion annuelle de la SOHO 2022 Dans ce commentaire, deux experts discutent des implications des données d’essais cliniques présentées lors de la réunion annuelle de la SOHO 2022 sur les traitements à base d’inhibiteurs BTK pour les patients atteints de leucémie lymphoïde chronique (LLC) ou de lymphome à cellules du manteau (LCM).

Share

Faculty

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Director, Lymphoma Program
Medical Director, Oncology Data Center
Assistant Professor
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Oncology
Emory University
Atlanta, Georgia

Kami Maddocks

Kami Maddocks, MD

Professor of Clinical Internal Medicine
Division of Internal Medicine
Department of Hematology
The Ohio State University
Lymphoma Program Director
The Ohio State University James Cancer Hospital
Columbus, Ohio

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Christopher R. Flowers, MD, MS

Director, Lymphoma Program
Medical Director, Oncology Data Center
Assistant Professor
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Oncology
Emory University
Atlanta, Georgia

Christopher R. Flowers, MD, MS: consulting/advisory/speaker: AstraZeneca, Bayer, BeiGene, BioAscend, Bristol-Myers Squibb, Celgene, Curio Sciences, Denovo Biopharma, Epizyme/Incyte, Foresight Diagnostics, Genentech/Roche, Genmab, MEI Pharmaceuticals, MorphoSys, N-Power, Pharmacyclics/Janssen, SeaGen; stock options: Foresight Diagnostics, N-Power; research funding (institution): 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceuticals, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm.

Kami Maddocks, MD

Professor of Clinical Internal Medicine
Division of Internal Medicine
Department of Hematology
The Ohio State University
Lymphoma Program Director
The Ohio State University James Cancer Hospital
Columbus, Ohio

Kami Maddocks, MD: consultant/advisor/speaker: AbbVie, Acerta, ADC Therapeutics, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Genentech, Genmab, Gilead, Incyte, Janssen, Kite, Lilly, MorphoSys, Pharmacyclics.